Medicus Pharma Ltd. (NASDAQ:MDCX)
| Market Cap | 3.58M-93.3% |
| Revenue (ttm) | 0 |
| Net Income | -39.15M-137.1% |
| EPS | -1.62-76.1% |
| Shares Out | 22.04M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,405,409 |
| Open | 0.16 |
| Previous Close | 0.16 |
| Day's Range | 0.15 - 0.16 |
| 52-Week Range | 0.15 - 3.05 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 1.00(+515.01%) |
| Earnings Date | Nov 13, 2026 |
About MDCX
Medicus Pharma Ltd., a biotechnology and life sciences enterprise, is dedicated to expediting the progression of innovative and groundbreaking medical treatments through their clinical development phases. A primary focus for the company is the creation of non-surgical solutions specifically targeting dermatological malignancies.
$MDCX stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in MDCX holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by MDCX's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
MDCX Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New MDCX patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to MDCX from public contracts
Source: USAspending.gov
MDCX Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from MDCX’s recent data — informational, not investment advice